Skip NavigationSkip to Content

Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors

  1. Author:
    Weiss, Jonathan
    Davies, Luke C.
    Karwan, Megan
    Ileva, Lilia
    Ozaki, Michelle K.
    Cheng, Robert
    Ridnour, Lisa
    Annunziata, Christina M.
    Wink, David
    McVicar, Daniel
  2. Author Address

    NCI, Canc & Inflammat Program, Ctr Canc Res, Frederick, MD 21701 USA.Cardiff Univ, Div Infect & Immun, Cardiff, S Glam, Wales.Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD USA.NCI, Womens Malignancies Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
    1. Year: 2018
    2. Date: Aug 31
  1. Journal: Journal of Clinical Investigation
  2. AMER SOC CLINICAL INVESTIGATION INC,
    1. 128
    2. 9
    3. Pages: 3794-3805
  3. Type of Article: Article
  4. ISSN: 0021-9738
  1. Abstract:

    Control of cellular metabolism is critical for efficient cell function, although little is known about the interplay between cell subset-specific metabolites in situ, especially in the tumor setting. Here, we determined how a macrophage-specific (M phi-specific) metabolite, itaconic acid, can regulate tumor progression in the peritoneum. We show that peritoneal tumors (B16 melanoma or ID8 ovarian carcinoma) elicited a fatty acid oxidation-mediated increase in oxidative phosphorylation (OXPHOS) and glycolysis in peritoneal tissue-resident macrophages (pResM phi). Unbiased metabolomics identified itaconic acid, the product of immune-responsive gene 1-mediated (Irg1-mediated) catabolism of mitochondrial cis-aconitate, among the most highly upregulated metabolites in pResM phi of tumor-bearing mice. Administration of lentivirally encoded Irg1 shRNA significantly reduced peritoneal tumors. This resulted in reductions in OXPHOS and OXPHOS-driven production of ROS in pResM phi and ROS-mediated MAPK activation in tumor cells. Our findings demonstrate that tumors profoundly alter pResM phi metabolism, leading to the production of itaconic acid, which potentiates tumor growth. Monocytes isolated from ovarian carcinoma patients' ascites fluid expressed significantly elevated levels of IRG1. Therefore, IRG1 in pResM phi represents a potential therapeutic target for peritoneal tumors.

    See More

External Sources

  1. DOI: 10.1172/JCI99169
  2. PMID: 29920191
  3. PMCID: PMC6118601
  4. WOS: 000443283400021

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel